Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,036,045.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $530.11, for a total value of $5,036,045.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $171,990,478.73. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Stock Down 2.7%

United Therapeutics stock traded down $14.16 during midday trading on Tuesday, reaching $515.50. The stock had a trading volume of 343,386 shares, compared to its average volume of 494,773. United Therapeutics Corporation has a 12 month low of $292.34 and a 12 month high of $609.35. The firm’s 50-day moving average price is $539.13 and its 200 day moving average price is $535.14. The firm has a market capitalization of $22.11 billion, a PE ratio of 18.44, a P/E/G ratio of 1.82 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business earned $6.41 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 26.32 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Geneos Wealth Management Inc. grew its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC bought a new stake in United Therapeutics during the second quarter valued at approximately $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia grew its stake in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent research reports. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.